Drug Trial Radar · NCT07190196
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
Sep 26, 2025
Primary completion
Jun 28, 2028
Study completion Dec 25, 2030
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD. The purpose of this study is to measure time to adjudicated IgG4-RD clinical disease flare, and other relevant efficacy endpoints including flare-free rate, control of IgG4-RD disease activity, use of GC rescue and safety parameters such as treatment-emergent adverse events, clinical laboratory values and electrocardiograms (ECG) in participants aged 18 years and above, diagnosed with IgG4-RD and treated with rilzabrutinib tablets over a 52-week placebo-controlled period. Study details include: The study duration will be up to 60 weeks, including a Screening period of 4 to 6 weeks, a 52-week double blind treatment period, and 2 weeks of follow up (plus an optional OLE of 108 weeks). The number of visits will be 16 (plus an optional 9 visits during the OLE).
Conditions
- Immunoglobulin G4 Related Disease
Interventions
RilzabrutinibDrug
Pharmaceutical form:Tablet-Route of administration:Oral
PlaceboDrug
Pharmaceutical form:Tablet-Route of administration:Oral
GlucocorticoidDrug
Pharmaceutical form:Tablet, solution, suspension formulations according to local standard practices-Route of administration:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first adjudicated clinical disease flare treated by the investigator during the Blinded Treatment periodTime frame: Until Week 52
Locations
95 sites in 19 countries. Site status is shown where the registry gives one.
Kaiser Permanente - Fontana Medical Center- Site Number : 8400015
Fontana, California · Recruiting
University of California Davis Health- Site Number : 8400012
Sacramento, California · Recruiting
San Jose Clinical Trials- Site Number : 8400016
San Jose, California · Recruiting
Solace Clinical Research - Tustin- Site Number : 8400020
Tustin, California · Recruiting
Life Clinical Trials - Margate - Colonial Drive- Site Number : 8400002
Margate, Florida · Recruiting
Vitalia Medical Research - Margate- Site Number : 8400025
Palm Beach Gardens, Florida · Recruiting
Tampa General Hospital - Tampa - General Circle- Site Number : 8400027
Tampa, Florida · Recruiting
Emory University School of Medicine - Atlanta- Site Number : 8400013
Atlanta, Georgia · Recruiting
Primeway Clinical Research- Site Number : 8400019
Fayetteville, Georgia · Recruiting
Massachusetts General Hospital- Site Number : 8400008
Boston, Massachusetts · Recruiting
Henry Ford Hospital- Site Number : 8400009
Detroit, Michigan · Recruiting
Mayo Clinic in Rochester - Minnesota- Site Number : 8400017
Rochester, Minnesota · Recruiting
Icahn School of Medicine at Mount Sinai- Site Number : 8400014
New York, New York · Recruiting
Arthritis and Osteoporosis Consultants of the Carolinas- Site Number : 8400035
Charlotte, North Carolina · Recruiting
Cleveland Clinic - Cleveland- Site Number : 8400001
Cleveland, Ohio · Recruiting
Ohio State University Wexner Medical Center- Site Number : 8400024
Columbus, Ohio · Recruiting
Paramount Medical Research and Consulting LLC- Site Number : 8400018
Middleburg Heights, Ohio · Recruiting
Stryde Research- Site Number : 8400011
Plano, Texas · Recruiting
Epic Medical Research - Red Oak- Site Number : 8400003
Red Oak, Texas · Recruiting
Digestive Health Research of North Texas- Site Number : 8400021
Wichita Falls, Texas · Recruiting
Velocity Clinical Research - Seattle- Site Number : 8400005
Seattle, Washington · Recruiting
Investigational Site Number : 0320004
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320002
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320006
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320005
Berazategui, Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320003
San Isidro, Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0560001
Leuven, Belgium · Recruiting
Investigational Site Number : 1240004
Montreal, Quebec, Canada · Recruiting
Investigational Site Number : 1240001
Sherbrooke, Quebec, Canada · Recruiting
Investigational Site Number : 1520005
Concepción, Biobio, Chile · Recruiting
Investigational Site Number : 1520006
Puente Alto, Reg Metropolitana de Santiago, Chile · Recruiting
Centro de estudios G y C-Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1560008
Beijing, China · Recruiting
Investigational Site Number : 1560004
Beijing, China · Recruiting
Investigational Site Number : 1560001
Beijing, China · Recruiting
Investigational Site Number : 1560012
Chengdu, China · Recruiting
Investigational Site Number : 1560010
Hangzhou, China · Recruiting
Investigational Site Number : 1560003
Jiazhuang, China · Recruiting
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.